Truist analyst Les Sulewski downgraded ANI Pharmaceuticals (ANIP) to Hold from Buy with a price target of $60, down from $80. Closure delays of the Alimera Sciences (ALIM) acquisition imply potential post due diligence issues, likely on manufacturing deficiencies of Yutiq, the analyst tells investors in a research note. The firm now sees increased execution risk if and when the deal closes and questions whether the $381M price tag justifies its initial peak sales forecast of $220M by 2030. Truist removed Alimera from its model and plans to “reassess at an appropriate time.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI says working in ‘good faith’ to close Alimera acquisition
- ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
- ANI Pharmaceuticals Announces Debt Clearance and Notes Sale
- ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes
- ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering